- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:22 | Celltrion Reports Record Q2 Earnings With Operating Profit of 242.5 Billion Won | 1 | BusinessKorea | ||
| 04:26 | Celltrion posts record Q2 earnings on sales expansion | 3 | Korea Times | ||
| 09.07. | Celltrion Announces Strategy Amid U.S. Tariff Plans | 1 | BusinessKorea | ||
| 08.07. | Celltrion USA Launches Denosumab Biosimilars in the U.S. | 2 | Contract Pharma | ||
| 08.07. | Celltrion Launches Bone Disease Treatments Stoboclo and Osenvelt in the U.S. | 1 | BusinessKorea | ||
| 08.07. | Celltrion USA Launches Denosumab Biosimilars, STOBOCLO And OSENVELT, In U.S. | 3 | RTTNews | ||
| 08.07. | Celltrion debuts denosumab biosimilars in U.S. | 1 | Korea Herald | ||
| 04.07. | Celltrion Holdings to spend $366 mil. to boost corporate value | 1 | Korea Times | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| 04.07. | Celltrion secures $730 mn to buy biosimilar unit shares, pursue M&A | 1 | Korea Economic Daily | ||
| 04.07. | Samsung Bioepis and Celltrion Set for Showdown in Korea's Osteoporosis Drug Market | 1 | BusinessKorea | ||
| 04.07. | Celltrion Secures 1 Trillion Won for Restructuring | 2 | BusinessKorea | ||
| 04.07. | Celltrion Holdings to spend 500 bln won to boost corporate value | 1 | Yonhap News | ||
| 03.07. | Celltrion Appeals Court Ruling in Dispute with Humasis | 2 | BusinessKorea | ||
| 26.06. | Celltrion to Buy Back Additional 100 Bil. Won in Shares to Boost Shareholder Value | 2 | BusinessKorea | ||
| 26.06. | Celltrion to repurchase 100 bln won in shares to boost shareholder value | 1 | Yonhap News | ||
| 23.06. | Celltrion Opens UK Headquarters in Uxbridge | 1 | Contract Pharma | ||
| 20.06. | Celltrion deepens global ties, unveils R&D vision at Bio U.S.A | 1 | Korea Herald | ||
| 19.06. | Celltrion UK: Celltrion opens new UK headquarters in Uxbridge, UK | 299 | Business Wire | New office located in the heart of Uxbridge underscores Celltrion's long-term business commitment in the UK
Celltrion UK has officially opened its new UK headquarters at the Charter Building... ► Artikel lesen | |
| 17.06. | FDA approves new presentation of Celltrion's SteQeyma for paediatric psoriasis | - | PMLiVE | ||
| 17.06. | Samsung, Celltrion, SK lead Korea's largest showing at Bio U.S.A 2025 | 1 | Korea Herald |
1 2 3 4 5 Weiter >>
127 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| EVOTEC | 7,456 | +0,59 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| ARVINAS | 7,350 | -5,34 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen | |
| TELOMIR PHARMACEUTICALS | 2,300 | +90,08 % | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
| VERVE THERAPEUTICS | 10,915 | -0,32 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
| ADMA BIOLOGICS | 16,730 | -4,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,500 | +2,29 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
| TARSUS PHARMACEUTICALS | 43,250 | +4,54 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| PROKIDNEY | 3,150 | -10,51 % | ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel | FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT... ► Artikel lesen |
Das Unternehmen CELLTRION INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.